晚期甲状腺癌靶向治疗和免疫治疗研究新进展  

Progress in targeted therapy and immunotherapy for advanced thyroid cancer

作　　者：毛爱红[1] 武元元[1] 王军[1] MAO Aihong;WU Yuanyuan;WANG Jun(Second Department of Head and Neck Surgery,Gansu Provincial Cancer Hospital,Lanzhou 730050,Gansu Province,China)

机构地区：[1]甘肃省肿瘤医院头颈二科,甘肃兰州730050

出　　处：《肿瘤》2022年第1期15-23,共9页Tumor

基　　金：甘肃省重点研发计划(20YF3FA021);甘肃省卫生行业科研项目(GSWSKY2020-19)

摘　　要：甲状腺癌是内分泌系统中最常见的恶性肿瘤。尽管绝大多数甲状腺癌为分化型甲状腺癌,治疗采用以手术为主的综合治疗手段,其预后良好,10年生存率超过90%,但对于晚期复发、转移和碘难治性甲状腺癌以及间变性甲状腺癌仍缺乏有效的治疗手段。近年来,随着分子生物学技术的迅猛发展,极大地提升了人们对不同亚型甲状腺癌发病机制的认识,尤其是一些新的甲状腺癌标志物的发现,为晚期甲状腺癌患者的个体化治疗带来了更多的希望。本文总结了对晚期甲状腺癌具有良好抗肿瘤活性和临床效益的靶向治疗及免疫治疗进展,以期为改善晚期甲状腺癌患者的预后提供参考。Thyroid cancer is the most common malignant tumor of endocrine system.Although the prognosis of most differentiated thyroid cancers is generally good and with a 10-year survival rate of more than 90%,there is still a lack of effective treatment for late recurrent,metastatic and radioactive iodine refractory thyroid cancer and anaplastic thyroid cancer.With the rapid development of molecular biology technology and the discovery of new biomarkers for thyroid cancer,which has significantly improved the understanding of the molecular pathogenesis of thyroid cancer,thus allowing more personalized treatments for patients with advanced thyroid cancer.This article reviews the current targeted therapy and immunotherapy for advanced thyroid cancer with good antitumor activity and clinical benefits,in order to improve the prognosis of patients with advanced thyroid cancer.

关 键 词：甲状腺癌 放射性碘难治性 晚期甲状腺癌 靶向治疗 免疫治疗 

分 类 号：R736.1[医药卫生—肿瘤]